SpyGlass Pharma, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
SpyGlass Pharma, Inc. (SGP) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $14.21 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2026-08-06
- SpyGlass Pharma, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2026-06-30 was $14.21, a 162.18% increase year-over-year.
- SpyGlass Pharma, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2026-03-31 was $11.86, a 170.78% increase year-over-year.
- SpyGlass Pharma, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2025-06-30 was $5.42.
- SpyGlass Pharma, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2025-03-31 was $4.38.
- SpyGlass Pharma, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2025 was $6.05, a 49.01% increase from fiscal 2024.
- SpyGlass Pharma, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2024 was $4.06.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month |
|---|---|---|---|
| 2026-06-30 | $14.21 10-Q · filed 2026-08-06 | $12.11 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $11.86 10-Q · filed 2026-05-14 | ||
| 2025-12-31 | $6.05 10-K · filed 2026-03-26 | ||
| 2025-06-30 | $5.42 10-Q · filed 2026-08-06 | $5.19 10-Q · filed 2026-08-06 | |
| 2025-03-31 | $4.38 10-Q · filed 2026-05-14 | ||
| 2024-12-31 | $4.06 10-K · filed 2026-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Beta Bionics, Inc. (BBNX) | United States | $0.979B | -9.66 |
| PROCEPT BioRobotics Corp (PRCT) | United States | $1.001B | -11.77 |
| SI-BONE, Inc. (SIBN) | United States | $0.830B | -49.82 |
| TANDEM DIABETES CARE INC (TNDM) | United States | $1.059B | -16.57 |
| IRADIMED CORP (IRMD) | United States | $1.089B | 52.92 |
| ARTIVION, INC. (AORT) | United States | $1.123B | -345.09 |
| MIMEDX GROUP, INC. (MDXG) | United States | $0.687B | 89.92 |
| ANGIODYNAMICS INC (ANGO) | United States | $0.632B | -13.02 |
| INTEGRA LIFESCIENCES HOLDINGS CORP (IART) | United States | $1.234B | -193.02 |
| ORTHOPEDIATRICS CORP (KIDS) | United States | $0.592B |